Ardea Biosciences, Inc. (Nasdaq: RDEA) announced that it has initiated a Phase 1/2 study of RDEA119, its lead mitogen-activated ERK ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE